Centrifuge as per normal procedures
Alpha-fetoprotein (AFP) is a glycoprotein with a single polypeptide chain and a molecular weight of approximately 70,000 Daltons. AFP is mainly synthesised in the liver, gastrointestinal tract and the yolk sac of the foetus and is secreted in the foetal serum, reaching a peak in the 13th week of pregnancy and then gradually decreases to healthy adult concentrations (<6kU/L) at about 1-2 years of age. With the exception of pregnancy, serum AFP concentrations remain low in a healthy adult. In adults the half-life of AFP in serum is approximately 5 days.
AFP is used as a tumour marker for the detection and monitoring of primary liver cell carcinomas (hepatocellular carcinomas) and germ cell tumours of the ovary and testis. In patients at risk of developing hepatocellular carcinoma, e.g. those with cirrhosis or chronic hepatitis, AFP determination can be used for early detection of carcinoma. Serum AFP concentration correlates with the size of the tumour and has some prognostic significance.
Elevated serum concentrations are also found in non-seminomatous testicular carcinomas. Serum AFP is useful in assessing response of the tumour to therapy, with successful treatment leading to a progressive fall in the AFP concentration with a return to normal. If AFP does not fall at the expected rate, this suggests the presence of residual tumour.
No specific patient preparation. Sample should be collected into a yellow or red top only.
Serum AFP concentrations may be elevated in several cancers e.g. gastric carcinoma, colorectal carcinoma, biliary carcinoma, pancreatic carcinoma and metastatic liver cancer, and in the following benign conditions: hepatitis, liver cirrhosis, Crohn’s disease, and polyposis. Elevated serum AFP concentrations are not absolute evidence of the presence of malignant disease, and should be used in conjunction with other diagnostic and clinical information.
AFP determination in maternal serum during pregnancy helps to establish open neural tube defects in the foetus. Relatively low AFP concentrations in maternal serum may be indicative of Down’s syndrome, hydatidiform mole or an undetected abortion. These are specialist applications and these services are provided by Birmingham Women’s Hospital.
0-7 KU/L
Copyright UHB Pathology 2018
Protection of Personal Information – Clinical Laboratory Services comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
University Hospitals Birmingham medical laboratories at Queen Elizabeth Hospital, Heartlands Hospital, Good Hope Hospital and Solihull Hospital are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/
Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further test information, please visit the test database: http://qehbpathology.uk/test-database
For further information contact Louise Fallon, Quality Manager, 0121 371 5962